IRVINE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- The Board of Directors of Endocare, Inc. (Nasdaq: ENDO) received on August 6, 2008 an unsolicited proposal from HealthTronics, Inc. (Nasdaq: HTRN) to purchase all of the outstanding shares of Endocare common stock for $2.28 per share in cash.
Endocare's Board of Directors, consistent with its fiduciary duties, and in consultation with its financial and legal advisors, will review and consider HealthTronics' unsolicited proposal carefully and promptly in the context of Endocare's strategic plans and pursue the best course of action for the long-term value to stockholders.
Endocare, Inc. -- http://www.endocare.com -- is an innovative medical
device company focused on the development of minimally invasive
technologies for tissue and tumor ablation. Endocare has initially
concentrated on developing technologies for the treatment of prostate
cancer and believes that its proprietary technologies have broad
applications across a number of markets, including the ablation of tumors
in the kidney, lung and liver and palliative intervention (treatment of
pain associated with metastases).
Investor Contact: Media Contact: For Additional Information:
Matt Clawson Len Hall Craig T. Davenport, CEO
Allen & Caron, Inc. Allen & Caron, Inc. Michael R. Rodriguez, CFO
(949) 474-4300 (949) 474-4300 Endocare, Inc.
|SOURCE Endocare, Inc.|
Copyright©2008 PR Newswire.
All rights reserved